Signs and Symptoms of Wet Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is the leading cause of legal adult blindness and severe visual impairment in developed countries.1

While once of the most common, there are other common causes of visual impairment in older adults is presbyopia, cataract, glaucoma, and diabetic retinopathy.2-4

Visual impairment by macular degeneration is a major health problem for older adults. Its impact on functional status and quality of life is quite remarkable.

Visual impairment caused by macular degeneration can limit the ability of older adults to ambulate, serve themselves, safely drive a car and is associated with increased rates of falls and hip fractures.5-7

Get Your FREE Eye Health Diet Plan

  • Nine most important vitamins for eye health
  • How to naturally protect and improve your eye health as you age
  • Developed exclusively by our medical doctor

By clicking “Download Now”, I agree to Ben's Natural Health Terms and Conditions and Privacy Policy.

What is macular degeneration?

Age-related macular degeneration (AMD) is a degenerative disease of the centermost part of the retina known as the “macula.” The disease results in loss of central vision, which is the sharpest vision humans have.

AMD is clinically classified as dry or wet, depending on the pathological stage. It was the general understanding in the past that dry AMD and wet AMD are two separate diseases.

However, it is well known nowadays that dry AMD progresses to wet AMD as a complication of the disease in some patients. The risk of developing wet AMD was estimated to be 1 to 5% every year and 13 to 18% every three years.8 That being said, it is important to understand that wet AMD accounts for more than 80% of cases of severe vision loss or legal blindness.9

In dry AMD, lesions in the retina include drusen deposits, atrophy of retinal epithelium, detachments of the pigment epithelium, and/or subretinal pigment epithelial clumping.

On the other hand, Wet AMD lesions are characterized by the growth of new blood vessels into the subretinal space, usually from the choroidal circulation. One may think that new blood vessels are a good thing, but these new vessels are very abnormally fragile. They leak, leading to collections of subretinal fluid or blood under the retina. These blood vessels are clinically known as choroidal neovascularization or CNV. 


In the early stages of age-related macular degeneration, patients are often asymptomatic. Patients with dry AMD may complain of a gradual loss of vision in one or both eyes.

  • Their first complaint usually is related to difficulty in reading or driving. They may also mention that they need brighter light or a magnifying glass when reading or performing fine tasks.10

  • When someone develops wet AMD, they usually present with acute visual distortion or sudden loss of central vision. This happens when a sudden subretinal hemorrhage or fluid starts to accumulate. Symptoms usually appear in one eye at a time.

  • One of the earliest changes with wet AMD is a distortion of straight lines.

  • Patients usually report that they see straight edges such as doors or window blinds as curved or distorted. Patients may also complain of a dark patch that appeared in their central vision.

  • Patients with advanced AMD lose their central vision in all scenarios, but they rarely lose their peripheral vision.


So far, it is still unclear what the real pathogenesis of age-related macular degeneration is. There has been some evidence related to abnormal components in the retinal pigment epithelium. Also, theories related to inflammation and ischemia were proposed in several studies as potential contributors to the pathogenesis.11-12

Specific genes have also been identified that could account for more than half of all cases of AMD. It was found that these factors influence the development and progression of the disease and different responses to treatments.13 

Hypoxia and ischemia have also been significant contributors, becoming a specific target for therapeutic management options, including smoking cessation and antioxidants. 

clear vision supplement

Risk factors

Researchers have identified numerous risk factors for age-related macular degeneration.14 These include the following:

  • Age: prevalence of AMD increases with age, especially for people over the age of 50.

  • Ethnicity: AMD is more prevalent in whites than in blacks, with an intermediate prevalence in Hispanics and Chinese.

  • Smoking: Smoking increases the risk of dry and wet AMD. It is also associated with an increased risk of progression from early to advanced AMD, geographic atrophy, and both eyes’ involvement.

  • Alcohol use: heavy alcohol use (Over three drinks per day) is associated with an increased early AMD risk.

  • Family history: patients with a family history of AMD have increased risk themselves.

  • Cardiovascular disease: a history of stroke or coronary artery disease is associated with increased risk for AMD.

  • AIDS: AIDS patients have been reported to have an increased incidence of AMD compared to that of HIV negative patients. 

  • Myeloproliferative diseases: patients with chronic myeloproliferative disorders, including thrombocythemia, polycythemia vera, and Myelofibrosis, have an overall increased AMD risk.

  • Medications: regular aspirin use is associated with an increased risk of both dry and wet AMD. There have been associations between the use of some medications and AMD, but more studies are yet to finalize the findings. 


While the most common and essential complication to avoid and focus on is bleeding from choroidal neovascularization, wet macular degeneration is associated with other complications. These include visual hallucinations (Charles Bonnet syndrome).15

It can also lead to retinal detachment, where the retinal tissue separates from the blood vessels. This can cause the sudden appearance of floaters, flashes, and reduced peripheral vision

When vision loss is substantial, it can commonly lead to depression, social isolation, and low self-esteem. It can also lead to a high risk of falling, particularly for seniors who already have full risks based on their medications or balance problems. 


Several healthy lifestyle habits were shown to help prevent age-related macular degeneration. These habits include diet, nutritional and vitamin supplements, physical activity, and smoking cessation.

The relationship between diet and the risk of AMD has been analyzed in several research studies.16-18 Healthy diets, particularly those high in carotenoids, lutein, zeaxanthin, and zinc, have been associated with decreased risk of AMD.

Adherence to a Mediterranean diet was associated with a reduction in the risk of progression to advanced AMD. In this study, which included nearly 5000 participants, greater adherence to a Mediterranean diet was associated with a 40% reduced risk of advanced AMD risk compared to lower adherence.19 Finally, greater fish intake, as well as omega-3 and omega-6 polyunsaturated fatty acids, are associated with a decreased risk of AMD.

Nutritional and vitamin supplements, including antioxidant vitamins, do not appear to be effective in preventing AMD. However, vitamin B preparations were shown to reduce the risk of developing AMD.20

Physical activity appears to have a protective effect, as well. In multiple studies, higher levels of physical activity were associated with a lower likelihood of developing early AMD.21

Smoking was shown to increase the risk of developing dry and wet AMD. We always discourage all patients from quitting smoking or avoiding initiating smoking. While it may seem surprising to many people, this also includes vaping with nicotine-containing products, as nicotine may exacerbate neovascularization. 22

Treatment Options

As a general rule, all patients should quit or avoid initiating smoking due to the increased risk of progression to advanced age-related macular degeneration (wet AMD).

It is also recommended that patients with risk factors evident on optical coherence tomography and other imaging modalities to be treated with a daily oral eye vitamin supplement (for example, Ocuvite, PreserVision).  

Doses should be consistent with age-related eye disease study-2 (AREDS-2) formulation (containing 500 mg of vitamin C, 400 international units of vitamin E, 10 mg of lutein, 2 mg of Zeaxanthin, 80 mg of zinc [as zinc oxide], and 2 mg of copper [as cupric oxide]. In the original AREDS formulation, one of the components also was beta-carotene, which has been associated with an increased risk of lung cancer, particularly in smokers. 

Non-smokers and the other is at low risk of lung cancer may still use the original formulation, if available. Antioxidants have been hypothesized to prevent cellular damage in the retina by limiting the effects of free radicals produced in the process of light absorption.23

Normal people with no AMD or patients with mild or borderline AMD have not been shown to benefit from antioxidant and/or zinc supplementation.

It was also studied whether adding additional antioxidants would further decrease AMD’s risk, but other additions did not reduce the progression of early AMD.

When it comes to wet age-related macular degeneration, special considerations are given. Effective therapies for wet AMD include intravitreous injection of a vascular endothelial growth factor (VEGF) inhibitor, also known as “anti-VEGF,” photodynamic therapy (PDT), and supplementation with zinc and antioxidant vitamins.

The decision about specific therapies must take into consideration the likelihood of visual recovery, which is better with smaller, more recent lesions, as well as the risks of the various therapies. This decision must be taken by an ophthalmologist and particularly a retina specialist. 24

Generally speaking, the current guidelines recommend for most patients with wet AMD to receive treatment with intravitreal bevacizumab, ranibizumab, or aflibercept. Photodynamic therapy (PDT) is no longer offered to patients.

It is also suggested that patients with wet AMD in one or both eyes be treated with daily oral supplements consistent with the AREDS-2 formulation that we already mentioned. Alternatively, patients who are non-smokers or former smokers may use the standard AREDS formulation, which contains beta-carotene rather than lutein or zeaxanthin. 

Our Eye Health Supplement: Clear Vision

Clear Vision is one of the leading all-natural, clinical-grade supplements, designed to work as part of a healthy diet and lifestyle to maintain optimal eye health.

clear vision

It contains several nutrients that have been recommended by the National Eye Institute to help reduce the risk of developing age-related Macular Degeneration (AMD).  

In addition to this, the ingredients in Clear Vision are clinically proven to support optimal eye health, improve vision sharpness, combat age-related vision loss, and protect against cataracts. 

Find out more about Clear Vision.


Age-related macular degeneration (AMD) is the leading cause of blindness in adults of developed countries. It affects the central portion of the retina that results primarily in loss of central vision. AMD is classified as dry or wet, depending on the stage.

The risk of AMD increases with age. Smoking has been identified as a major modifiable risk factor. Symptoms of wet AMD usually appear in one eye even though the disease does affect both eyes. When a patient presents with a visual disturbance complaint, they require urgent ophthalmic evaluation by a board-certified ophthalmologist, preferably a retina specialist. Treatment options include antioxidant agents as well as anti-VEGF injections. 


  1. Hyman L. Epidemiology of eye diseases in the elderly. Eye (London) 1987; 1 (Pt 2): 330
  2. Weih LM, VanNewkirk MR, McCarty CA, Taylor HR. Age-specific causes of bilateral visual impairment. Arch Ophthalmol 2000; 118:264
  3. Holz FG, Wolfensberger TJ, Piguet B, et al. Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors. Ophthalmology 1994; 101:1522
  4. Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual imparment in an older population: the Rotterdam Study. Arch Ophthalmol 1998; 116:653
  5. Felson DT, Anderson JJ, Hannan MT, et al. Impaired vision and hip fracture. The Framingham Study. J Am Geriatr Soc 1989; 37:495
  6. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767
  7. Lord SR, Dayhew J. Visual risk factors for falls in older people. J Am Geriatr Soc 2001; 49:508
  8. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004; 291:1900
  9. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008; 358:2606
  10. Quillen DA. Common causes of vision loss in elderly patients. Am Fam Physician 1999; 60:99
  11. Joachim N, Colijn JM, Kifley A, et al. Five-year progression of unilateral age-related macular degeneration to bilateral involvement: the Three Continent AMD Consortium report. Br J Ophthalmol 2017; 101:1185
  12. Seddon JM, George S, Rosner B, Rifai N. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol 2005; 123:774.
  13. Despriet DD, van Duijn CM, OOstra BA, et al. Complement component C3 and risk of age-related macular degeneration. Ophthalmology 2009; 116:474.
  14. Hyman L, Neborsky R. Risk factors for age-related macular degeneration for age-related macular degeneration: an update. Curr Opin Ophthalmol 2002; 13:171.
  15. Symptoms and Complications of macular degeneration. Updated February 6, 2019. 
  16. Mares JA, VOland RP, Sondel SA, et al. Healthy lifestyles related to subsequent prevalence of age-related macular degeneration. Arch Ophthalmol 2011; 129:470.
  17. Cho E, Seddon JM, Rosner B, et al. Prospective study of intake of fruits, vegetables, vitamins, and carotenoids and risk of age-related maculopathy. Arch Ophthalmol 2004; 122:883.
  18. Tan JS, Wang JJ, Flood V, et al. Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountain Eye Study. Ophthalmology 2008; 115:334.
  19. Merle BM, Coljin JM, Cougnard-Gregoire A, et al. Mediterranean Diet and Incidence of Advanced Age-related Macular Degeneration: The EYE-RISK Consortium. Ophthalmology. 2019; 126:381.
  20. Christen WG, Glynn RJ, Chew EY, et al. Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women’s Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med 2009; 169:335.
  21. McGuinness MB, Le J, Mitchell P, et al Physical Activity and Age-related Macular Degeneration: A Systematic Literature Review and Meta-analysis. Am J Ophthalmol 2017; 180:29.
  22. Suner IJ, Espinosa-Heidmann DG, Marin-Castano ME, et al. Nicotine increases size and severity of experimental choroidal neovascularization. Invest Ophthalmol Vis Scie 2004; 45:311. 
  23. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation and vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119-1417.
  24. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2-year findings of the IVAN randomized controlled trial. Lancet 2013; 382:1258.

Top Products

Total Health


Glucose Control